U.S. Hospitality Stock News

NasdaqGS:MPWR
NasdaqGS:MPWRSemiconductor

A Look At Monolithic Power Systems (MPWR) Valuation After Recent Share Price Volatility

Why Monolithic Power Systems Is On Investors’ Radar Monolithic Power Systems (MPWR) has attracted attention after recent share price swings, including a 2.2% decline in the latest session, a roughly 1.5% gain over the past week, and a month drop of about 11%. See our latest analysis for Monolithic Power Systems. The recent 11.2% 30 day share price pullback comes after a stronger 90 day share price return of 13.1% and a 1 year total shareholder return of 82.4%, so momentum still skews positive...
NasdaqGS:HTHT
NasdaqGS:HTHTHospitality

How Investors May Respond To H World Group (HTHT) Earnings Beat, Bigger Cash Returns And Cautious Outlook

H World Group has reported its 2025 results, showing higher revenue and net income, confirmed completing a US$156.31 million share buyback, declared a US$400 million cash dividend for the second half of 2025, issued 2026 revenue guidance, outlined new hotel openings and closures, and announced a CFO transition effective March 18, 2026. An interesting aspect for investors is the combination of rising earnings and a larger cash return to shareholders, alongside relatively cautious 2026 revenue...
NasdaqGS:SMCI
NasdaqGS:SMCITech

Super Micro Co Founder Exit Puts Compliance And Export Risks In Focus

Super Micro Computer (NasdaqGS:SMCI) co-founder Yih-Shyan “Wally” Liaw has resigned following a federal indictment tied to alleged export-control violations. The company has appointed DeAnna Luna as acting Chief Compliance Officer as part of an immediate governance response. These moves come as the legal case advances from individual charges to changes at the board and senior compliance level. Super Micro Computer, known for its server and data center hardware, sits at the center of growing...
NasdaqGS:FORM
NasdaqGS:FORMSemiconductor

Has FormFactor (FORM) Run Too Far After 196% One Year Share Price Surge?

If you are wondering whether FormFactor's current share price lines up with its underlying worth, this article will walk you through what the numbers are actually saying. The stock recently closed at US$92.22, with returns of 2.6% over 7 days, a 2.5% decline over 30 days, 55.8% year to date and 196.4% over 1 year that may catch your eye. Recent coverage has focused on FormFactor as a semiconductor testing specialist, with investors watching how its technology and customer exposure position...
NYSE:HUBB
NYSE:HUBBElectrical

Assessing Hubbell (HUBB) Valuation After Positive Conference Update And Q1 Demand Momentum

Hubbell (HUBB) is back in focus after management used the JPMorgan Industrials Conference on March 18 to outline a constructive first quarter outlook, highlighting strong demand across utility, data center, and light industrial markets. See our latest analysis for Hubbell. The share price has eased back recently with a 9.68% 1 month share price return and a 3.43% 1 day move lower to US$475.74. However, the 1 year total shareholder return of 42.35% and 5 year total shareholder return of...
NYSE:G
NYSE:GProfessional Services

Evaluating Genpact (G) After Recent Share Price Swings And Undervaluation Claims

Genpact (G) has been catching investor attention after recent share price swings, with the stock now trading around $38.70. That move comes alongside mixed short term returns and weaker performance over the past year. See our latest analysis for Genpact. These short term share price moves sit against a weaker picture over longer periods, with a 90 day share price return of a 20.21% decline and a 1 year total shareholder return of a 21.15% decline, which suggests recent optimism is still...
NasdaqCM:TGTX
NasdaqCM:TGTXBiotechs

TG Therapeutics Credit Deal And Valuation Gap Catch Investor Attention

TG Therapeutics, ticker NasdaqCM:TGTX, announced a new five year, $750 million senior secured credit facility with Blue Owl Capital. The agreement is described as non dilutive, meaning it does not involve issuing new equity to raise capital. The facility includes repayment of prior debt and could expand to as much as $1b in total available financing. TG Therapeutics focuses on developing and commercializing therapies in the biopharmaceutical space, where access to sizeable, flexible capital...
NYSE:MOD
NYSE:MODBuilding

Is It Too Late To Consider Modine Manufacturing (MOD) After Its Strong Multi Year Rally?

If you are wondering whether Modine Manufacturing at around US$196.55 still offers value after a major price increase, or if you might be late to the story, this article breaks down what the current price reflects. The stock has seen a 4.2% gain over the last 7 days, a 13.2% decline over 30 days, a 39.6% return year to date, and a 121.9% return over the past year. These moves naturally raise questions about both upside potential and changing risk. Recent coverage has focused on Modine as a...
NYSE:MA
NYSE:MADiversified Financial

UK Payment Sovereignty Push What It Could Mean For Mastercard Investors

Senior UK bankers are reported to be exploring a domestic payment system that would operate independently of Mastercard and Visa. The proposed sovereign network would handle card payments within the UK using homegrown infrastructure. This effort is framed as part of a broader push for payment sovereignty and could affect international schemes like NYSE:MA if it progresses. For Mastercard (NYSE:MA), the UK is an important international market where it provides card processing and related...
NasdaqGS:ZION
NasdaqGS:ZIONBanks

A Look At Zions Bancorporation (ZION) Valuation After Recent Share Price Weakness

Recent share performance and business scale Zions Bancorporation National Association (ZION) has drawn investor attention after a recent stretch of mixed share performance, including a 13.5% decline over the past month and a 10.2% decline in the past 3 months. Over a longer horizon, the stock shows a 12.8% total return over the past year and a multi year total return above 7x. The company reports annual revenue of US$3.3b and net income of US$884 million. See our latest analysis for Zions...
NYSE:KD
NYSE:KDIT

Is Kyndryl Holdings (KD) Starting To Look Attractive After A 64.7% One Year Surge

For readers considering whether Kyndryl Holdings at around US$12.21 is starting to look like value or remains a stock to approach with caution, this article breaks down what the current price may be implying. The shares have faced heavy pressure, with a 1 year return of 64.7% and a year to date move of 52.1%. This naturally raises questions about both potential upside and perceived risk. Recent coverage has focused on how Kyndryl continues to trade as a stand alone IT services provider after...
NYSE:AJG
NYSE:AJGInsurance

How a Board Retirement and RBC’s Positive View At Arthur J. Gallagher (AJG) Has Changed Its Investment Story

Arthur J. Gallagher & Co. reported that director Sherry Barrat informed the company on March 6, 2026 of her decision to retire from the Board, effective May 12, 2026, after which the Board will shrink from ten to nine members. Her retirement, alongside recent analyst commentary, sharpens investor focus on how board composition and external views may shape oversight of the company’s ongoing growth plans and risk management priorities. We’ll now examine how RBC’s renewed positive coverage,...
NasdaqGS:MMYT
NasdaqGS:MMYTHospitality

Is It Time To Reassess MakeMyTrip (MMYT) After A 60% One Year Share Price Slide

If you are wondering whether MakeMyTrip at around US$39.78 is starting to look like value or still carries more risk than reward, you are not alone. The stock has seen sharp moves, with returns of 12.6% decline over 7 days, 29.0% decline over 30 days, 51.4% decline year to date and 60.6% decline over 1 year, even though the 3 year and 5 year returns sit at 65.3% and 23.7% respectively. Recent coverage has focused on how this volatility affects sentiment toward online travel platforms and...
NasdaqGS:PRGS
NasdaqGS:PRGSSoftware

Is There Now An Opportunity In Progress Software (PRGS) After A 42% One Year Pullback?

Investors may be wondering whether Progress Software's current share price reflects its true value, or if the recent weakness is opening up an opportunity. The stock closed at US$31.29, with returns of an 8.8% decline over 7 days, a 22.4% decline over 30 days, a 23.8% decline year to date, and a 42.5% decline over 1 year. These moves may have shifted how the market views its risk and reward trade off. Recent headlines have focused on Progress Software's role as a software provider and how...
NasdaqGS:ROKU
NasdaqGS:ROKUEntertainment

Roku (ROKU) Valuation Check After Recent Share Price Swings

Roku stock snapshot after recent performance swings Roku (ROKU) has been trading through mixed recent moves, with a 2.7% decline over the past day, a small gain over the past week, and a roughly 15% drop in the past 3 months. See our latest analysis for Roku. Roku’s recent 1 month share price return of 4.73% contrasts with a 90 day share price decline of 15.05%. The 1 year total shareholder return of 19.13% points to stronger past rewards than the 5 year total shareholder return, which is...
NYSE:BX
NYSE:BXCapital Markets

Blackstone (BX) Valuation Check As Private Debt Redemption Limits Stir Concern Over Credit And AI Default Risks

Blackstone (BX) is in focus after reports that it has limited redemptions from certain private debt funds, alongside peers like BlackRock and Morgan Stanley, as concerns about private credit and AI related default risks build. See our latest analysis for Blackstone. At a share price of US$110.43, Blackstone’s 90 day share price return of 29.13% and year to date share price return of 30.46% mark a sharp pullback. However, the 3 year total shareholder return of 44.39% and 5 year total...
NYSE:ELF
NYSE:ELFPersonal Products

Is It Time To Reassess e.l.f. Beauty (ELF) After Recent Share Price Volatility

If you are wondering whether e.l.f. Beauty is attractively priced or just riding a wave of enthusiasm, the current share price of US$72.50 makes that a timely question. The stock has recently seen a 1.2% decline over the last week, a 22.9% decline over the past month, yet is still up 15.4% over the last year and 167.4% over five years, which can change how risk and return feel for new and existing shareholders. Recent coverage has focused on e.l.f. Beauty as a prominent name in the US beauty...
NasdaqGS:UPWK
NasdaqGS:UPWKProfessional Services

Assessing Upwork (UPWK) Valuation After A 47% Three Month Share Price Decline

Why Upwork Stock Is Drawing Attention Now Upwork (UPWK) is back on many watchlists after a stretch of weak returns, including a 47% decline over the past 3 months. This has prompted investors to reassess its recent financial profile. See our latest analysis for Upwork. The recent 47% 90 day share price decline, on top of a 43% year to date share price return and a 17% 1 year total shareholder return, suggests momentum has been fading as investors reassess both growth prospects and risks...
NasdaqGM:SION
NasdaqGM:SIONBiotechs

A Look At Sionna Therapeutics (SION) Valuation After A 166% One Year Share Price Gain

Sionna Therapeutics (SION) is back in focus for investors after recent trading left the shares with a return of about 166% over the past year, contrasting with weaker near term moves. See our latest analysis for Sionna Therapeutics. The share price is currently US$36.39, and short term share price returns over 1 and 3 months have been weak, yet the 1 year total shareholder return of about 166% points to strong earlier momentum that has recently cooled. If you are looking beyond a single...
NasdaqGS:HLNE
NasdaqGS:HLNECapital Markets

Hamilton Lane Expands Essential Retail Exposure With Tenaya Village Recap Deal

Hamilton Lane (NasdaqGS:HLNE) has partnered with CenterSquare Investment Management to recapitalize Tenaya Village, a suburban Las Vegas retail center. The firm becomes the asset's majority investor, expanding its role in GP led secondary deals tied to essential service retail. The transaction signals active interest in real assets and alternative deal structures beyond traditional private credit and fund vehicles. Hamilton Lane enters this deal with its shares at $99.59 and a mixed return...
NYSE:WD
NYSE:WDDiversified Financial

Is It Time To Reassess Walker & Dunlop (WD) After Its Sharp Share Price Swings?

If you are wondering whether Walker & Dunlop at around US$43.82 is starting to look like value, the recent share performance gives plenty to think about. The stock has seen a 2.6% decline over the past week, a 30.7% decline over the last month, and returns of 25.4% year to date and 46.7% over the past year, with a 33.2% and 51.6% decline over the last 3 and 5 years respectively. These moves have put valuation front and center for many investors who are reassessing what they are willing to...
NYSE:RES
NYSE:RESEnergy Services

Is RPC (RES) Fairly Priced After Its Strong Multi Year Share Price Performance

If you are wondering whether RPC at US$6.83 is priced attractively or not, the starting point is understanding what the current market price might be implying about its future. Over the short term, the stock has returned 4.8% in the last 7 days, 12.0% over 30 days, 23.5% year to date, 28.6% over 1 year, and 38.1% over 5 years, while the 3 year return sits at a 4.0% decline. Recent coverage around RPC has focused on how investors are reassessing energy service providers, with attention on...
NasdaqCM:SGML
NasdaqCM:SGMLMetals and Mining

Sigma Lithium Sales Restart And New Fines Deal Shape Valuation Debate

Sigma Lithium (NasdaqCM:SGML) has resumed industrial scale sales of premium lithium concentrate. The company has completed its first major sale of high purity lithium fines. The transaction covers 400,000 tonnes of premium lithium fines at a fixed price. Management highlights this as opening up significant new profit streams and improving sales visibility. Sigma Lithium, a producer of battery grade lithium materials, now has fresh evidence of executed sales to match the attention around its...
NasdaqGS:PCVX
NasdaqGS:PCVXBiotechs

Will VAX-31’s Phase 3 OPUS Progress and Broader Serotype Coverage Change Vaxcyte’s (PCVX) Narrative

Vaxcyte recently reported in The Lancet Infectious Diseases that its 31-valent pneumococcal conjugate vaccine candidate VAX-31 showed strong immune responses and a safety profile similar to Prevnar 20 in a Phase 1/2 study of 1,015 adults aged 50 and older, and has since advanced the high-dose regimen into the OPUS Phase 3 adult program. An important insight from these data is that VAX-31 met or exceeded regulatory immunogenicity criteria for all 31 serotypes at higher doses while covering...